BOMBSHELL FDA email turns trans ‘health care’ narrative on its head

Evidence shows ‘treatments’ increase risk of depression, suicide

FIRST ON THE DAILY SIGNAL—A team leader at the U.S. Food and Drug Administration recommended approving “puberty blockers” for teens who identify as transgender even while noting that a recent study showed these drugs are associated with an “increased risk in depression and suicidality.”

Many activists claim that children struggling with gender dysphoria (the persistent condition of identifying with the gender opposite their biological sex) must receive experimental drugs to make their bodies resemble bodies of the opposite sex to stop them from committing suicide, yet the FDA study suggested these drugs actually increase the risk of suicide.

In one email on Jan. 25, 2022, Shannon Sullivan, clinical team leader at the FDA’s Division of General Endocrinology, noted that the agency’s Division of Metabolism and Endocrinology Products performed a “safety review of the GnRH agonist class in pediatric patients in 2016/2017.” GnRH stands for “Gonadatropin-releasing hormone,” and GnRH agonists prevent the natural release of testosterone and estrogen that initiate puberty.

…

Read Full Article Here…(wnd.com)

---

Home | Caravan to Midnight (zutalk.com)

Live Stream + Chat (zutalk.com)

We Need Your Help to Keep Caravan To Midnight Going,

Please Consider Donating to Help Keep Independent Media Independent